HR Execs on the Move

RotaChrom

www.rotachrom.com

 
RotaChrom Technologies is the inventor and first worldwide manufacturer of the Industrial Scale Centrifugal Partition Chromatography (iCPC) platforms. The company revolutionizes the pharmaceutical and cannabis industries by manufacturing and selling unique inventions of a special purifying technology. A cost-efficient and easily adaptable separation solution is offered for active pharmaceutical ingredients (API) and cannabinoids. The cost and the risk profile of R&D, as well as production can be significantly lower by using CPC tools, thereby pharmaceutical and cannabis-based products can become more widely available. Since its establishment, the company has achieved massive international success in pharmaceutical and pharma-graded cannabis purification. It has ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.rotachrom.com
  • 300 Spectrum Center Drive
    Irvine, CA USA 92618
  • Phone: 661.768.2247

Executives

Name Title Contact Details

Similar Companies

Elk Hill

Elk Hill enables children and families to transform overwhelming challenges into successful futures by offering behvioral health and education services.

KP Consulting

KP Consulting Inc. is a West Chester, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Madrigal Pharmaceuticals

Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, resmetirom, also known as MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in NASH. Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal has initiated a Phase 3 clinical study in NASH patients with advanced liver fibrosis, MAESTRO-NASH, in which the primary endpoint after one year of dosing is resolution of NASH and key secondary endpoints include LDL-cholesterol lowering and reduction in liver fibrosis. Clinical benefit in reducing progression to more advanced liver disease, including cirrhosis, is a long-term goal of this trial. A second Phase 3 clinical study, MAESTRO-NAFLD-1, has also been initiated. This 52-week non-invasive study in a broader segment of NASH patients will provide additional safety information to support the NASH indication and will include key efficacy endpoints: LDL-cholesterol lowering, triglyceride lowering, reduction of liver fat as determined by MRI-PDFF, as well as reduction of elevated liver enzymes and reduction in fibrosis biomarkers. This is a non-biopsy study in people with NASH, as documented using non-invasive techniques or historical liver biopsy.

HealthEconomics.Com

HealthEconomics.Com is the worlds most comprehensive and credible website for resources and jobs in healthcare value and market access.

Aurobindo Pharma Limited

Aurobindo Pharma Limited is a pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India.